Drug Development in Obesity

Back Bay’s monthly healthcare roundup covers drug development in obesity, including:

A brief introduction to glucagon-like peptide 1 (GLP-1) agonists
Why GLP-1s’ popularity is skyrocketing as treatment for type 2 diabetes and obesity
How amylin and petrelintide (a long-acting amylin analogue) are being newly re-imagined for the obesity space, as well as muscle-targeted approaches like myostatin and activins
Where BD and investor interest lies as these drugs are expected to have north of $150B in sales annually within the next decade
What’s happening in early to late-stage drug development
What the future holds for this sector, possibly to include cannabinoid one receptor inverse agonists and mitochondrial targets for metabolic disease